Axim Biotechnologies Stock Performance
| AXIM Stock | USD 0.02 0 21.43% |
Axim Biotechnologies holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.6, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Axim Biotechnologies are expected to decrease at a much lower rate. During the bear market, Axim Biotechnologies is likely to outperform the market. Use Axim Biotechnologies total risk alpha and the relationship between the potential upside and day typical price , to analyze future returns on Axim Biotechnologies.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Axim Biotechnologies are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very abnormal forward indicators, Axim Biotechnologies displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 457.2 K | |
| Total Cashflows From Investing Activities | -50.5 K |
Axim |
Axim Biotechnologies Relative Risk vs. Return Landscape
If you would invest 0.80 in Axim Biotechnologies on October 28, 2025 and sell it today you would earn a total of 0.90 from holding Axim Biotechnologies or generate 112.5% return on investment over 90 days. Axim Biotechnologies is currently generating 2.1443% in daily expected returns and assumes 14.1571% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Axim, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Axim Biotechnologies Target Price Odds to finish over Current Price
The tendency of Axim Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.02 | 90 days | 0.02 | about 19.92 |
Based on a normal probability distribution, the odds of Axim Biotechnologies to move above the current price in 90 days from now is about 19.92 (This Axim Biotechnologies probability density function shows the probability of Axim Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Axim Biotechnologies has a beta of -0.6. This suggests as returns on the benchmark increase, returns on holding Axim Biotechnologies are expected to decrease at a much lower rate. During a bear market, however, Axim Biotechnologies is likely to outperform the market. In addition to that Axim Biotechnologies has an alpha of 2.013, implying that it can generate a 2.01 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Axim Biotechnologies Price Density |
| Price |
Predictive Modules for Axim Biotechnologies
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Axim Biotechnologies. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Axim Biotechnologies Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Axim Biotechnologies is not an exception. The market had few large corrections towards the Axim Biotechnologies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Axim Biotechnologies, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Axim Biotechnologies within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.01 | |
β | Beta against Dow Jones | -0.6 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.14 |
Axim Biotechnologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Axim Biotechnologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Axim Biotechnologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Axim Biotechnologies is way too risky over 90 days horizon | |
| Axim Biotechnologies has some characteristics of a very speculative penny stock | |
| Axim Biotechnologies appears to be risky and price may revert if volatility continues | |
| Axim Biotechnologies has high likelihood to experience some financial distress in the next 2 years | |
| Axim Biotechnologies currently holds 5.06 M in liabilities with Debt to Equity (D/E) ratio of 1.36, which is about average as compared to similar companies. Axim Biotechnologies has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Axim Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Axim Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axim Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axim to invest in growth at high rates of return. When we think about Axim Biotechnologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 60.46 K. Net Loss for the year was (16.03 M) with profit before overhead, payroll, taxes, and interest of 60.46 K. | |
| Axim Biotechnologies currently holds about 65.16 K in cash with (2.49 M) of positive cash flow from operations. | |
| Roughly 41.0% of Axim Biotechnologies shares are held by company insiders |
Axim Biotechnologies Fundamentals Growth
Axim Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Axim Biotechnologies, and Axim Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Axim Pink Sheet performance.
| Return On Equity | -100.19 | |||
| Return On Asset | -0.35 | |||
| Operating Margin | (847.86) % | |||
| Current Valuation | 13.6 M | |||
| Shares Outstanding | 186.44 M | |||
| Price To Earning | (53.71) X | |||
| Price To Book | 2.86 X | |||
| Price To Sales | 943.93 X | |||
| Revenue | 60.46 K | |||
| EBITDA | (13.42 M) | |||
| Cash And Equivalents | 65.16 K | |||
| Total Debt | 5.06 M | |||
| Debt To Equity | 1.36 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (2.49 M) | |||
| Earnings Per Share | (0.13) X | |||
| Total Asset | 5.32 M | |||
| Retained Earnings | (36.37 M) | |||
| Current Asset | 1.18 M | |||
| Current Liabilities | 2.55 M | |||
About Axim Biotechnologies Performance
By examining Axim Biotechnologies' fundamental ratios, stakeholders can obtain critical insights into Axim Biotechnologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Axim Biotechnologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.Things to note about Axim Biotechnologies performance evaluation
Checking the ongoing alerts about Axim Biotechnologies for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Axim Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Axim Biotechnologies is way too risky over 90 days horizon | |
| Axim Biotechnologies has some characteristics of a very speculative penny stock | |
| Axim Biotechnologies appears to be risky and price may revert if volatility continues | |
| Axim Biotechnologies has high likelihood to experience some financial distress in the next 2 years | |
| Axim Biotechnologies currently holds 5.06 M in liabilities with Debt to Equity (D/E) ratio of 1.36, which is about average as compared to similar companies. Axim Biotechnologies has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Axim Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Axim Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axim Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axim to invest in growth at high rates of return. When we think about Axim Biotechnologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 60.46 K. Net Loss for the year was (16.03 M) with profit before overhead, payroll, taxes, and interest of 60.46 K. | |
| Axim Biotechnologies currently holds about 65.16 K in cash with (2.49 M) of positive cash flow from operations. | |
| Roughly 41.0% of Axim Biotechnologies shares are held by company insiders |
- Analyzing Axim Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Axim Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Axim Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Axim Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Axim Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Axim Biotechnologies' pink sheet. These opinions can provide insight into Axim Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.